Skip to main content

Table 3 Top 20 medications that contributed to the anticholinergic burden score in dementia patients with high exposure prior to 2–10 years of dementia according to the scales

From: Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale

Drug

Total (N = 1,324)

KABS (N = 916)

ACB (N = 975)

Number of patients (%)

Average DDD per patient per year

score

Contribution to high exposure (%)

score

Contribution to high exposure (%)

chlorpheniraminea, b

1,297

(98.0)

17

3

5.8

3

5.2

tramadola

1,262

(95.3)

9.2

2

2.3

0

0

cimetidinea, b

1,260

(95.2)

46.7

2

11.6

1

4.0

diazepama, b

1,198

(90.5))

34.8

1

4.2

1

3.4

ranitidinea, b

1,150

(86.9)

28.6

1

3.1

1

3.0

hydrochlorothiazideb

974

(73.6)

80.2

0

0

1

10.1

alprazolama, b

921

(69.6)

32.5

1

4.1

1

3.2

dimenhydrinatea, b

869

(65.6)

33.3

3

11.3

3

11.7

amitriptylinea, b

727

(54.9)

10.9

3

3.8

3

3.4

theophyllinea, b

664

(50.2)

13.8

1

1.5

1

1.5

furosemidea, b

606

(45.8)

39.5

1

4.3

1

5.0

atenololb

549

(41.5)

33

0

0

1

4.3

lorazepama

515

(38.9)

11.9

1

1.5

0

0

nifedipineb

459

(34.7)

38

0

0

1

5.2

triazolama

454

(34.3)

15.8

1

2.1

0

0

octylonium bromidea

451

(34.1)

4.5

3

1.8

0

0

tolterodinea, b

355

(26.8)

7.9

3

2.7

3

2.8

propiverinea, b

342

(25.8)

6.3

3

2.2

3

2.2

isosorbideb

290

(21.9)

40.2

0

0

1

5.4

doxazosinb

263

(19.9)

18.1

0

0

1

2.4

digoxinb

215

(16.2)

13.3

1

1.2

1

1.7

paroxetinea, b

209

(15.8)

9.3

2

2.1

3

3.5

quinupraminea

188

(14.2)

5.1

3

2.2

0

0

solifenacina, b

174

(13.1)

6.1

3

2.1

3

2.3

levodopa and decarboxylase inhibitora

166

(12.5)

12.6

1

1.8

0

0

beztropineb

77

(5.8)

3.6

3

1.4

3

1.3

amantadinea

76

(5.7)

6.3

2

1.8

2

1.1

  1. DDD Defined daily dose, KABS Korean Anticholinergic Burden Scale, ACB Anticholinergic Cognitive Burden
  2. aTop 20 medications to contribute to anticholinergic burden in high exposure group with KABS
  3. bTop 20 medications to contribute to anticholinergic burden in high exposure group with ACB